key: cord-0889691-rbw4onmm authors: Kiszewski, Anthony E.; Galkina Cleary, Ekaterina; Jackson, Matthew J.; Ledley, Fred D. title: NIH funding for vaccine readiness before the COVID-19 pandemic date: 2021-03-08 journal: Vaccine DOI: 10.1016/j.vaccine.2021.03.022 sha: 92ce2785dc3a3e49b360a12d0ff0148b53cf000c doc_id: 889691 cord_uid: rbw4onmm Rapid development of vaccines for COVID-19 has relied on the application of existing vaccine technologies. This work examines the maturity of ten technologies employed in candidate vaccines (as of July 2020) and NIH funding for published research on these technologies from 2000–2019. These technologies vary from established platforms, which have been used successfully in approved products, to emerging technologies with no prior clinical validation. A robust body of published research on vaccine technologies was supported by 16,358 fiscal years of NIH funding totaling $17.2 billion from 2000–2019. During this period, NIH funding for published vaccine research against specific pandemic threats such as coronavirus, Zika, Ebola, and dengue was not sustained. NIH funding contributed substantially to the advance of technologies available for rapid development of COVID-19 vaccines, suggesting the importance of sustained public sector funding for foundational technologies in the rapid response to emerging public health threats. Clinical Trial Registry: not applicable The COVID-19 pandemic has triggered a rapid mobilization of global vaccine development. With infection fatality rates approaching 1% [1] , the prospect of long-term sequelae in those who recover [2, 3] , and a high level of population immunity required to halt transmission [4] , initiatives have proceeded at "warp speed" [5, 6] . The urgency of vaccine development necessitated the application of existing vaccine technologies. Within six months of the first description of the SARS-CoV-2 virus [7] , candidate vaccines employing many diverse methodologies entered development [8] . Some candidates incorporated technologies that had already been validated in successful products. Others incorporated technologies that had been previously shown to generate immune responses against human coronaviruses including Middle East Respiratory Syndrome virus (MERS-CoV) [9] and SARS-CoV-1 [10] . Some candidates applied technologies from registered veterinary vaccines against coronaviruses in domesticated species, including (chicken) Infectious Bronchitis Virus (IBV) [11] and bovine Betacoronavirus-1 [12] . Nascent technologies, such as genetically modified viral vectors or mRNA also played an important role, even though these technologies were not previously validated in clinical trials or registered products. Rapid success of these initiatives was not guaranteed. Despite successful development of many vaccines, the challenge remained daunting. As late as 2013, evidence showed that the failure rate for vaccines entering development was as high as 94%, and that the average time from preclinical studies to approval was 10.7 years [13] . Research on technological innovation has demonstrated that the maturation level, or readiness, of many different technologies has been a critical determinant in their ability to generate products that satisfy market needs [14] [15] [16] [17] [18] [19] . Using a bibliometric model for the advance of basic biomedical research, we have found that few targeted therapeutics are successfully developed before research on both the drug target and therapeutic modality pass an analytically described established point, and that timelines of clinical development are significantly shorter when clinical trials commence after this point [20, 21] . Similarly, the maturation of vaccine technologies is recognized to be a factor in the success of vaccine development. For example, a model of vaccine development prepared for the Coalition for Epidemic Preparedness Innovations (CEPI) posits that technologies with "no licensure track-record," have a substantially higher risk of failure than "well-established" technologies [22] . This is consistent with the suggestion that the high failure rate of vaccines in development prior to 2013 was due, in part, to the large number of candidate vaccines using unproven, nucleotide (DNA or RNA) technologies [13] . Research on the basic science and technologies underlying new drugs or vaccines, and the maturation of these technologies to the point that they can support efficient development, is funded primarily by the public sector, principally governments. We have previously examined the scale of NIH funding for the basic research and technologies underlying new drug approvals by identifying NIH funding cited in published research papers [21, 23] . These studies show that the NIH contributed more than $170 billion for research related to the 356 drugs approved from 2010-2019 or their drug targets, with more than 85% of this funding involving research on the drug targets rather than the drugs themselves. We have also observed that the majority of this research is funded through investigator-initiated research projects [21] . The present work examines the maturation of research on the technologies being used in candidate COVID-19 vaccines as well as the NIH funding supporting this research over the past twenty years. Specifically, we examine published research on vaccines incorporating attenuated or inactivated viruses, synthetic (recombinant) proteins, DNA or mRNA, or recombinant viral vectors as well as research on formulations including conventional adjuvants, virus-like particles, nanoparticles and toll-like receptor 9 (TLR9) agonists. We also examine research and NIH funding for vaccines aimed at coronaviruses and three unrelated viral pathogens that have been associated with epidemic transmission, Zika, Ebola, and dengue. We consider the impact of this prior research on accelerated efforts to develop a vaccine for COVID-19, and the importance of sustained public-sector funding in establishing a foundation for responding to pandemic outbreaks. Technologies utilized in candidate vaccines against COVID-19 were identified from the World Health Organization (WHO) "DRAFT Landscape of Candidate COVID-19 vaccines" [24] Viruses with epidemic potential were identified from Plotkin [25] or the WHO Blueprint [26] . Searches were performed using PubMed (www.pubmed.gov; accessed June 3, 2020), with the updated Automatic Term Mapping (May, 2020) optimized with Medical Subject Headings (MeSH) terms or Boolean modifiers to increase specificity (Supplemental Table 1 ). PubMed Identifiers (PMIDs) with their respective publication year were recorded. PMIDs acknowledging NIH funding were identified in NIH RePORTER data tables (https://exporter.nih.gov/ExPORTER_Catalog.aspx; accessed June 3, 2020) as described previously [23] . Each PMID was associated with a project year corresponding to the project number and year of publication using the "Link Tables for Project to Publication Associations." Costs (since 2000) were derived from the "Project Data Table. The bibliographic Technology Innovation Maturation Evaluation (TIME) model assesses the maturation of a body of published research by modeling the rate of research accumulation, as described previously [20] . The model quantifies the "S-curve" of technology maturation described in other sectors [14] [15] [18] [19] ]. The TIME model fits an exponentiated logistic function to the accumulation of PubMed identified publications over time. The equation has the form: Where N is the cumulative number of publications, L is the upper limit of publications, r is the growth rate, t is time, and t 0 is midpoint of exponential growth. This asymmetric, sigmoidal function exhibits the common logistic sigmoid function ("S-curve") over log scales. The established (Te) point is defined as the point of minimum acceleration or logN''(t) min . Results are visualized as annual publications, cumulative publications, or log cumulative publications to assess the suitability of the calculated curve fit. As of July 31, 2020, the WHO listed 165 candidate vaccines against COVID-19 [24] . PubMed searches were performed for ten of the technologies utilized in this portfolio of products. The ten technologies and the number of publications through 2019 are shown in Table 1 . The time course of publications on the ten technologies together is shown in Figure 1A and other products since the 1950s. Research on these technologies has continued to accumulate since 1980 without evident acceleration or deceleration ( Figure 1A ). These technologies were used in four of the first ten candidate vaccines to enter clinical trials against COVID-19, but only 12 (7.3%) candidate vaccines through July 31, 2020. Synthetic vaccines incorporating recombinant proteins emerged with biotechnology in the 1980s. Exponential growth of research on synthetic vaccines was evident after 1985, but growth has slowed since the late 1990s ( Figure 1A ). While only one of the first ten candidate COVID-19 vaccines to enter clinical trials employed synthetic vaccine technologies, they are used in 66 (40%) candidate vaccines through July 31, 2020. Vaccines employing recombinant viral vectors emerged in the mid-1990s as an outgrowth of research on gene therapy. A period of exponential growth was evident in the 1990s, followed by slowing from the early 2000s to the present ( Figure 1A ). Two of the first ten candidate COVID- The total numbers of PMIDs, number and percent of NIH-funded PMIDs, project years, and project costs for ten vaccine technologies are shown in Table 1 . We identified 51,530 unique publications related to these ten vaccine technologies, including 8,420 (16%) acknowledging The type of research funding is shown in Figure 3A and Supplemental Table 2 . While 40% of project years associated with research on these technologies represented investigator-initiated research projects, these accounted for only 8.9% of project costs. A greater fraction of funding involved cooperative agreements (44%), intramural programs (9.4%), and research program projects and centers (22.7%). This pattern resembles that observed for the foundational research underlying remdesivir [28] , but differs sharply from that for other drugs approved from 2010-2019, where the majority of project years and costs involved investigator-initiated research projects [21] . Table 1 shows the number of PMIDs, NIH-funded PMIDs, project years, and project costs associated with vaccine development for each of these pathogens as well as for HIV, which has been the subject of intensive vaccine research since the 1980s. Figure 4A shows the annual NIH project costs for Ebola, Zika, dengue, and coronavirus vaccines since 2000 compared to the project costs for research on HIV vaccines. Figure 4B shows the annual NIH project costs for vaccine research on Ebola, Zika, dengue, and coronaviruses individually. Figure 3B and Supplemental Table 2 show the activity code categories for the NIH projects associated with published research on coronavirus vaccines. While the majority of project years were associated with investigator-initiated research projects, only 14% of project costs were associated with research projects, while 34% went to cooperative agreements, 26% to intramural programs, and 22% to research program projects and centers. This analysis was undertaken in the context of evidence that there is a 94% failure rate for vaccines entering development with an average clinical development time of more than 10 years [13] , the exigency for rapid development of a COVID-19 vaccine [5, 6] , and evidence that maturity of the underlying technologies is a significant factor in the efficiency of drug development [20, 21] . Using quantitative methods, we examined published research on ten [20, 21, 29] . Similarly, few products utilizing monoclonal antibodies [19] , nucleotide therapeutics [30] , or gene therapies [31] were approved before research on these modalities passed the established point. Evidence also shows that the timelines of clinical development from Phase 1 to approval is significantly shorter when clinical trials commence after the underlying technologies have passed this point [20, 21] . While the association between the point of maximum slowing of publication activity (the established point) and increased efficiency of product development is entirely empirical, it is likely that the slowing of publication activity reflects a stage in the advance of research when experiments are less likely to produce novel, publishable findings or introduce unanticipated new areas of investigation. So too, clinical investigations undertaken once the research has advanced to this stage may be more likely to achieve the predicted outcomes. It should be cautioned that, while the TIME model has been extensively validated in studies of drug development, it has not been previously applied to vaccines. Published literature on vaccine development, however, suggests that the maturation of technology is an important factor in vaccine development as well. The success of the Salk vaccine was preceded by unsuccessful efforts to develop products using analogous technologies, and the rollout of the Salk vaccine itself was complicated by an outbreak of polio caused by inadequate inactivation of early batches of the product [32] . Similarly, early versions of vaccines for RSV and measles led to enhanced disease on re-exposure [33] . More recently, the dramatic decline in the success rate for vaccine development from 2003-2013 has been ascribed, in part, to numerous failures of then nascent DNA technologies [34] . In contrast, the remarkable safety of vaccines currently approved by the FDA [35] , as well as the routine development of annual vaccines for evolving strains of influenza virus, are consistent with the efficiency of established vaccine technologies. A relationship between technological maturity and the efficiency of vaccine development is incorporated in an economic model of vaccine development prepared for CEPI. In this model, vaccine technologies with no "licensure track-record" are assumed to have a higher risk of vaccine failure and higher development costs than "well-established" technologies [22] . While there is no "licensure track-record" for mRNA vaccines, this analysis suggests that research on mRNA vaccine technologies is just now achieving a level of technology maturation associated with product success. The dramatic success of mRNA COVID-19 vaccines is also consistent with research on innovation suggesting that technologies which are not yet capable of meeting the performance standards of established markets, often generate important products that have a lower performance threshold [14, 15, 19] . In this context, the fact that the level and duration of gene expression required to stimulate an immune response may be lower than that required to achieve sustained, therapeutic levels of a protein, as well as the fact that clinical outcomes can be achieved without repetitive, long-term administration of the product, may have contributed to the early success of vaccines based on these technologies. It is also noteworthy that mRNA vaccines were able to enter preclinical and clinical development months earlier than vaccines using conventional technologies, because nucleotide products can be synthesized, produced, and formulated using established, standard methods. In contrast, candidate vaccines using attenuated live virus, inactivated virus, or purified proteins required production and purification of virus or antigens with novel properties, requiring custom processes for production and quality control. Viral vector vaccines employing adenoviral vectors also progressed rapidly through production and preclinical testing using standardized procedures. This progress was facilitated by the fact that two MERS vaccines utilizing these technologies had been previously produced and tested in Phase 1 clinical trials, before the waning of MERS precluded further testing [36, 37] , and these technologies have advanced past the analytically-defined established point estimated by the model. The cost of vaccine discovery and development typically relies on both public and private sector investments. A 1997 report by the National Vaccine Advisory Committee concluded that "two thirds of all new vaccines provided worldwide have been produced by a US network of independent industrial, governmental, and academic partners engaged in vaccine research and development" [38] . A 2001 report by the World Bank, working with Gavi, the Vaccine Alliance, described the role of public-sector institutions as being primarily focused on basic science "measured by the number and value of the research manuscripts they publish in the scientific literature" [39, 40] . In contrast, industry focused on development, manufacture, and marketing of vaccine products [39] , and more than 90% of all vaccine doses procured in the past five years have been manufactured by for-profit organizations [41] . A lack of sustainable investment is recognized as a limiting factor in developing vaccines for pandemic threats, particularly those initially impacting low-income countries [42] . Three of the four specific diseases examined in this report (coronavirus, Zika, and Ebola) were identified by the WHO as pandemic risks in the 2016 "R&D Blueprint for Action to prevent Epidemics" [26] and identified as priority epidemic infectious diseases by CEPI [22] . Our analysis describes a sporadic pattern of NIH funding related to these pathogens. In each case, we show that outbreaks of disease trigger an increase in grant-funded publication activity, which then wanes rapidly. The dramatic decrease in grant-funded publications related to coronavirus vaccines after 2015, despite recognition of coronavirus as a pandemic threat in the 2016 WHO report, is particularly striking. While this decrease may, in part, be due to the inability to conduct clinical trials of candidate products in the absence of active human infections, and uncertainty regarding the strains that may emerge in the future, mechanisms should be explored to sustain research aimed at preventing recognized pandemic threats, rather than simply responding to outbreaks of disease. Our work also demonstrates that while the largest fractions of PMIDs and project years represented investigator-initiated research projects, a majority of the funding was associated with cooperative agreements or intramural research, two mechanisms for funding governmentinitiated research programs, or for research capacity through research program projects and centers. This pattern has been observed previously in examining the foundational research underlying development of remdesivir [28] , but is distinctly different from NIH funding related to drugs in other therapeutic areas, where the large majority of research funding involves investigator-initiated research projects or research program projects and centers [21] . The lack of investigator-initiated, vaccine-focused research projects funded by the NIH is consistent with the observation that traditional grant mechanisms may not represent a robust mechanism for funding vaccine technologies or development [42] , and demonstrates the importance of continued strategic initiatives by governments or non-governmental organizations. Finally, this analysis emphasizes that NIH funding does not guarantee successful vaccine development. Despite decades of research and billions of dollars in NIH funding, there are no approved vaccines for HIV. In contrast, the NIH contributed little funding to the published research describing vaccines for Ebola or dengue viruses prior to approval of these products. There are several important limitations to this study. First, this analysis is restricted to published research included in PubMed, and may not capture reports, patents, regulatory filings, unpublished clinical studies, or trade secrets. Also, this method is dependent on the efficiency of PubMed searches, and may not identify research without abstracts in PubMed or research that predates emergence of standard vocabularies and might be missed by search algorithms. Second, it is not possible to associate costs with every NIH-funded publication due to incomplete RePORTER data and inconsistencies between publication dates and project years. Moreover, given an estimated lag of up to three years between research funding and publication [43] , funding for research performed since 2018 may be underrepresented in this analysis. developing and procuring the vaccine in response to the pandemic, should be considered in fully assessing the public sector's contribution to these products, their price, and the distribution of profits arising from their sale. These findings also demonstrate the importance of sustained public sector funding for foundational technologies in the ability to respond rapidly to emerging public health threats. Significantly, the majority of the NIH funding identified in this study came in the form of government-initiated cooperative agreements or intramural research, rather than investigatorinitiated research projects. Even so, we observed a lack of sustained research or funding related to recognized, epidemic threats, including coronavirus, over the past two decades. Further consideration needs to be given to creating robust mechanisms for sustained funding of research on vaccines for recognized pandemic threats to ensure a rapid response to future outbreaks of disease. Data are shown on a log scale, which illustrates the classic "S-curve" pattern of technological advance seen in other fields of technology. Estimating The infection fatality rate among symptomatic COVID-19 cases In the United States: Study estimates the COVID-19 infection fatality rate at the US county level A contemporary review of neurological sequelae of COVID-19 Cardiac sequelae of novel coronavirus disease 2019 (COVID-19): A clinical case series Estimating the number of infections and the impact of nonpharmaceutical interventions on COVID-19 in 11 European countries Developing a SARS-CoV-2 vaccine at warp speed A strategic approach to COVID-19 vaccine R&D A novel coronavirus from patients with pneumonia in China DRAFT landscape of COVID-19 candidate vaccines. World Health Organization MERS-CoV vaccine candidates in development: The current landscape Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus A candidate modified-live bovine coronavirus vaccine: Safety and immunogenicity evaluation Risk in vaccine research and development quantified Exploring the limits of the technology S-curve. Part I: component technologies The innovator's dilemma: When new technologies cause great firms to fail Better management of technology development can improve weapon system outcomes. General Accounting Office, www.gao.gov/products/NSIAD-99-162 Effective R&D operations in the '80s: Boosting the payoff from R&D Patterns of technological innovation in biotech Timelines of translational science: From technology initiation to FDA approval Government as the first investor in biopharmaceutical innovation Estimating the cost of vaccine development against epidemic infectious diseases: A cost minimisation study Contribution of NIH funding to new drug approvals 2010-2016 DRAFT Landscape of candidate COVID-19 vaccines Vaccines for epidemic infections and the role of CEPI Health Organization, An R&D blueprint for action to prevent epidemics Developing mRNA-vaccine technologies Foundational research and NIH funding enabling Emergency Use Authorization of remdesivir for COVID-19 Landscape of innovation for cardiovascular pharmaceuticals: From basic science to new molecular entities As technologies for nucleotide therapeutics mature, products emerge Why commercialization of gene therapy stalled; Examining the life cycles of gene therapy technologies Lock in, the state and vaccine development: Lessons from the history of the polio vaccines Consensus Summary Report for CEPI/BC Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines Vaccine R&D: Past performance is no guide to the future Postmarketing safety of vaccines approved by the US Food and Drug Administration: A cohort study Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label, nonrandomised, uncontrolled, phase 1 trial United States vaccine research: A delicate fabric of public and private collaboration Vaccines where they're needed Successes and failures: Worldwide vaccine development and application Vaccines and global health: In search of a sustainable model for vaccine development and delivery Metrics associated with NIH funding: A high-level view This work was supported by a grant from the National Biomedical Research Foundation, Waltham, MA, to Bentley University. The funding source had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.The authors thank Prateet Shah for his contributions to this manuscript as well as Drs. Michael Boss and Nancy Hsiung for their constructive suggestions. The authors declare no conflict of interest. All authors attest they meet the ICMJE criteria for authorship. Data used in this article are available from scholars.bentley.edu (Digital Commons).